# Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

> **NCT00286416** · NA · UNKNOWN · sponsor: **Scripps Clinic** · enrollment: 60 (—)

## Conditions studied

- Asthma
- Allergic Rhinitis

## Interventions

- **DRUG:** omalizumab (Xolair)

## Key facts

- **NCT ID:** NCT00286416
- **Lead sponsor:** Scripps Clinic
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2008-07
- **Target enrollment:** 60 (—)
- **Last updated:** 2006-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00286416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00286416, "Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00286416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*